Keywords

Details

Category:

Thesis, nostrification

Type:

praca doktorska pracowników zatrudnionych w PG oraz studentów studium doktoranckiego

Language:

Polish

Publication year:

2018

Bibliography: test

1. W Polsce występują zarówno kliniczne, środowiskowe i weterynaryjne izolaty A. fumigatus oporne na azole. Wśród przebadanych 200 izolatów oporność wynosiła 8,5% (w tym wśród klinicznych 3,6%, wśród środowiskowych 2,2% wśród weterynaryjnych 78,6%).
2. Wśród izolatów A. fumigatus występujących w Polsce istnieją różne mechanizmy oporności na azole. Należą do nich mutacja TR 34 L98H w genie CYP51A oraz nadekspresja genów kodujących pompy błonowe i genów odpowiedzialnych za poprawną budowę ściany i błony komórkowej grzybów. open in new tab
3. Obecność w medium hodowlanym posakonazolu lub itrakonazolu może powodować zmiany w kolorze grzybni grzybów z gatunku A. fumigatus. open in new tab
4. Obecność w medium hodowlanym badanych azoli indukuje u grzybów z gatunku A. fumigatus zwiększoną produkcję zarodników. open in new tab
5. Długotrwała obecność itrakonazolu, posakonazolu albo worikonazolu w środowisku może indukować oporność na azole wśród szczepów A. fumigatus. open in new tab
6. Obecność w medium hodowlanym itrakonazolu i worikonazolu powoduje wzrost ekspresji genów MDR1, MDR2, MDR3, ATRF, CYP51A, CYP51B grzybów A. fumigatus bez względu na mutacje występujące w genie CYP51A. open in new tab
7. Obecność w medium hodowlanym posakonazolu powoduje wzrost poziomu ekspresji genów MDR1, MDR2, MDR3, ATRF, CYP51A, CYP51B izolatów A. fumigatus bez mutacji TR 34 L98H, zaś w przypadku izolatów z tą mutacją powoduje spadek poziomu ekspresji genów CYP51B, MDR2, MDR3, ATRF a także nie powoduje istotnych zmian w poziomach ekspresji genów CYP51A i MDR1. open in new tab
8. Nadekspresja genów kodujących transportery błonowe oraz genów odpowiedzialnych za poprawną budowę ściany i błony komórkowej grzybów z gatunku A. fumigatus może przyczynić się do nabycia oporności na azole. open in new tab
9. Izolaty A. fumigatus oporne wyłącznie na itrakonazol charakteryzują się nadekspresją genu CYP51A.
10. Izolaty oporne na worikonazol, itrakonazol i posakonazol nie są wrażliwe na działanie izawukonazolu, a inne izolaty A. fumigatus mogą być oporne na izawukonazol pomimo braku oporności na pozostałe triazole. BIBLIOGRAFIA 1. open in new tab
11. Ahmad S, Joseph L, Hagen F, Meis J, Khan Z. 2015. Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. J. Antimicrob. Chemother. 70, 412-415. open in new tab
12. Ahmad S, Khan Z, Hagen F, Meis J. 2014. Occurrence of triazole-resistant Aspergillus fumigatus with TR 34 /L98H mutations in outdoor and hospital environment in Kuwait. Environ. Res. 133, 20-26. open in new tab
13. Alanio A, Sitterle E, Liance M, Farrugia C, Foulet F, Botterel F, Hicheri Y, Cordonnier C, Costa J, Bretagne S. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66, 371-374. open in new tab
14. Alvarez-Moreno C, Lavergne R, Hagen F, Morio F, Meis J, Le Pape P. 2017. open in new tab
15. Azole-resistant Aspergillus fumigatus harboring TR 34 L98H, TR 46 /Y121F/T289A and TR 53 mutations related to flower Fields In Colombia. Scientific Reports Nature. 7, 1- 8. open in new tab
16. Albarrag A, Anderson M, Howard S, Robson G, Warn P, Sanglard D, Denning D. 2011. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51a promoter. Antimicrob. Agents Chemother. 55, 5113-5121. open in new tab
17. Alzacar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela L. 2008. Aspergillus Section Fumigati: Antifungal susceptibility Patterns and sequence-based identification. Antimicrobial Agents and Chemotcherapy. 52(4), p. 1244-1251. open in new tab
18. Arabatzis M, Kambouris M, Kyprianou M, Chrysaki A, Foustoukou M, Kanellopoulou M, Kondyli L, Kouppari G, Koutsia-Karouzou C, Lebessi E, et al. 2011. Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece. Antimicrob. Agents Chemother. 55, 3025-3030.Araujo R, Pina-Vaz C, Rodrigues A. 2007. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus. Int. J. Antimicrob. Agents. 29, 108-111. open in new tab
19. Astvad K, Jensen R, Hassan T, Mathiasen E, Thomse G, Pedersen U, Christensen M, Hilberg O, Arendrup M. 2014. First detection of TR 46 /Y121F/T289A and TR 34 /L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob. Agents Chemother. 58, 5096-5101. open in new tab
20. Azevedo M, Faria-Ramos I, Costa Cruz L, Pina-Vaz C, Gon al es Rodrigues A. 2015. Genesis of azole antifungal resistance from agriculture to clinical settings. Journal of Agricultural and Food Chemistry. 63(34), pp.7463-7468. open in new tab
21. Badali H, Vaezi A, Haghani I, Yazdanparast S, Hedayati M, Mousavi B, Ansari S, Hagen F, Meis J, Chowdhary A. 2013. Environmental study of azole-resistant Aspergillus fumigatus with TR 34 /L98H mutations in the cyp51A gene in Iran. Mycoses 56, 659-663. open in new tab
22. Bader O, Tunnermann J, Dudakova A, Tangwattanachuleeporn M, Weig M, Gross U. 2015. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob. Agents Chemother. 59, 4356-4359. open in new tab
23. Bader O, Weig M, Reichard U, Lugert R, Kuhns M, Christner M, Held J, Peter S, Schumacher U, Buchheidt D. 2013. Cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob. Agents Chemother. 57, 3513-3517. open in new tab
24. Balajee S, Lindsley M, Iqbal N, Ito J, Pappas P, Brandt M. 2007. Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods. J. Clin. Microbiol. 45, 2701-2703. open in new tab
25. Barrs V, van Dorn T, Houbraken J, Kidd S, Martin P, Pinheiro M, Richardson M, Varga J, Samson R. 2013. Aspergillus felis sp. Nov. An Emerging agent of invasive aspergillosis in humans, cats, and dogs. PLOS One. 8(6), 1-11. open in new tab
26. Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung R. 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48, 197-200 open in new tab
27. Berger S, El Chazli Y, Babu A, Coste A. 2017. Azole resistance in Aspergillus fumigatus: a consequence of antifungal use in agriculture? Frontiers in Microbiology. 8(1024), 1-6. open in new tab
28. Blatzer M, Barker B, Willger S, Backmann N, Blosser S, Cornish E, Mazurie A, Grahl N, Haas H, Cramer E. 2011. SREBP coordinates iron and ergosterol homeostasis to mediate triazole drug and hypoxia responses in the human fungal pathogen Aspergillus fumigatus. PLOS Genet. 4, e1002374. open in new tab
29. Blosser S, Cramer R. 2012. SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A). Antimicrobial agents and chemotherapy. 56(1), 248-257. open in new tab
30. Brillowska-Dąbrowska A, Saunte D, Arendrup M. 2007. Five-hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. J. Clin. Microbiol. 45(4), 1200-1204. open in new tab
31. Brillowska-Dąbrowska A, Świerkowska A, Saunte D, Arendrup M. 2010. Diagnostic PCR test for Microsporum audouinii, M. canis and Trichophyton infections. Med. Mycol. 48(3), 486-490. open in new tab
32. Brillowska-Dąbrowska A, Mroczyńska M, Nawrot U, Włodarczyk K, Kurzyk E. 2015. Examination of cyp51A and cyp51B expression level of the first Polish azole resistant clinical Aspergillus fumigatus isolate. Acta Biochimica Polonica, 62(4), str. 837-839. open in new tab
33. Bromley M, van Muijlwijk G, Fraczek M, Robson G, Verweij P, Dening D, Bowyer P. 2014. Occurrence of azole-resistant species Aspergillus in the UK environment. J. Glob. Antimicrob. Resist. 2(4), 276-279. open in new tab
34. Brüggemann R, Alffenaar J, Blijle ens N, Billaud E, Kosterink J, Verweij P, Saravolatz L. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases. 48(10), 1441-1458. open in new tab
35. Bueid A, Howard S, Moore C, Harrison E, Bowyer P, Denind D. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob Chemother. 65(10), 2116-2118. open in new tab
36. Bueid A, Moore C, Dening D, Bowyer P. 2013. Hight-level expression of cyp51B in azole-resistant clinical Aspergillus fumigates isolates. J. Antimicrob. Chemother. 68(3), 512-514. open in new tab
37. Burgel P, Baixench M, Amsellem M, Audureau E, Chapron J, Kanaan R, Honore I, Dupouy-Camet J, Dusser D, Klaassen C. et al. 2012. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56, 869-874. open in new tab
38. Burgos A, Zaoutis T, Dvorak C, Hoffman J, Knapp K, Nania J, Steinbach W. 2008. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 121(5), 1286-1294. open in new tab
39. Camps S, Dutilh B, Arendrup M, Rijs A, Snelders E, Huynen M, Verweij P, Melchers W. 2012. Discovery of a hapE mutation that causes azole resisatnce in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLOS One. 7, e50034. open in new tab
40. Camps S, van der Linden J, Li Y, Kuijper E, van Dissel J, Verweij P, Melchers W. 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: A case study and review of the literature. Antimicrob. Agents Chemother. 56, 10-16. open in new tab
41. Claire L, Parker J, Warrilow A, Kelly D, Kelly S. 2015. Azole fungicides - understanding resistance mechanisms in agricultural fungal pathogens. Pest Manag Sci. 71, 1054-1058.
42. Chamilos G, Kontoyiannis D. 2005. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resistance Updates. 8(6), 344-358. open in new tab
43. Chowdhary A, Kathuria S, Randhawa H, Gaur S, Klaassen C, Meis J. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. Journal of Antimicrobial Chemotherapy. 67, pp.362-366. open in new tab
44. Chowdhary A, Kathuria S, Xu J, Sharma C, Sundar G, Singh P, Gaur S, Hagen F, Klaassen C, Meis J. 2012. Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR34/L98H mutations in the cyp51A gene in India. PLoS One. 7, e52871. open in new tab
45. Chowdhary A, Sharma C, Hagen F, Meis J. 2014. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 9, 697-711. open in new tab
46. Chowdhary A, Sharma C, Kathuria S, Hage, F, Meis J. 2015. Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front. Microbiol. 6, 428. open in new tab
47. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis J. 2014. Azole-resistant Aspergillus fumigatus with the environmental TR 46 /Y121F/T289A mutation in India. J. Antimicrob. Chemother. 69, 555-557. open in new tab
48. Chowdhary A, Sharma C van den Boom M, Yntema J, Hagen F, Verweij P, Meis J.F. 2014. Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. J. Antimicrob. Chemother. 2014, 69 2979-2983. open in new tab
49. Chryssanthou E. 1997. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand. J. Infect. Dis. 29, 509-512. open in new tab
50. Croft C, Culibrk L, Moore M, Tebbutt S. 2016. Interaction of Aspergillus fumigatus conidia with airway epithelial cells: a critical review. Front Microbiol. 7(472), 1-15 open in new tab
51. da Sliva Ferreira M, Malavazi I, Savoldi M, Brakhage A, Goldman M, Kim H, Nierman W, Goldman G. 2006. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet. 50(1), 32-44.
52. Dannaoui E, Borel E, Monier M, Piens M, Picot S, Persat F. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47, 333-340 open in new tab
53. Davidson A, Chen J. 2004. ATP-binding cassette transporters in bacteria. Annual Review of Biochemistry. 73(1), 241-268. open in new tab
54. Deng S, Zhang J, Ji Y, Verwiej P, Tsui K, Hageen F, Houbraken J, Meis J, Abliz P, Wang X, Zhao J, Liao W. 2017. Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China. Emerging Microbes&Infections. 6, 1-6. open in new tab
55. Dening D, Venkateswarluk K, Oakley K, Anderson M, Manning N, Stevens D, Warnock D, Kelly S. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents. Chemother. 41(6), 1364-1268. open in new tab
56. Dening D, Perlin D. 2011. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol. 6, 1229-1232. open in new tab
57. Diaz-Guerra T, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela J. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 48(3), 1071. open in new tab
58. Dirr F, Echtenacher B, Heesemann J, Hoffmann P, Ebel F, Wagener J . 2010. AfMkk2 is required for cell wall integrity signalling, adhesion, and full virulence of the human pathogen Aspergillus fumigatus. Int. J. Med. Microbiol. 300(7), 496-502. open in new tab
59. Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J.2013. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob. Agents Chemother. 57, 2815-2820. open in new tab
60. Escribano P, Recio S, Pelaez T, Gonzalez-Rivera M, Bouza E, Guinea J. 2012. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: Presence of heteroresistant populations. Antimicrob. Agents Chemother. 56, 174-178. open in new tab
61. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild M, Wisplinghoff H, Kronke M, Hamprecht A, 2014. Prevalence and molecular characterization of azole resistance in Aspergillus spp. Isolates from German cystic fibrosis patients. J. Antimicrob. Chemother. 69, 1533-1536. open in new tab
62. Fuhren J, Voskuil W, Boel C, Haas P, Hagen F, Meis J, Kusters J. 2015. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J. Antimicrob. Chemother. 70, 2894-2898. open in new tab
63. García-Valcárcel A, Tadeo J. 2011. Determination of azoles in sewage sludge from Spanish wastewater treatment plants by liquid chromatography-tandem mass spectrometry. Journal of Separation Science. 34(11), pp.1228-1235. open in new tab
64. García-Valcárcel A, Loureiro I, Escorial C, Molero E, Tadeo J. 2015. Uptake of azoles by lamb's lettuce (Valerianella locusta L.) grown in hydroponic conditions. Ecotoxicology and Environmental Safety. 124, pp.138-146. open in new tab
65. Georgopapadakou N, Walsh T. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrobial Agents and Chemotherapy. 40(2), 279- 291. open in new tab
66. Gerstl B, Weidman W, Newmann A. 1948. Pulmonary Aspergillosis: Report of two cases. Annals of Internal Medicine. 28, 662-671. open in new tab
67. Goncalves S, Souza A, Chowdhary A, Meis J, Colombo A. 2016. Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses. 59, 198-219. open in new tab
68. Goodall S, Lane J, Warnock D. 1984. The diagnosis and treatment of a case of nasal aspergillosis in a cat. J. Small. Anim. Pract. 25, 627-633. open in new tab
69. Gregson L, Goodwin J, Johnson A, McEntee L, Moore C, Richardson M, Hope W, Howard S. 2013. In vitro susceptibility of Aspegrillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole and posaconazole. Antimicrobial Agents and Chemotherapy. 57(11), 5778-5780. open in new tab
70. Hachem R, Kontoyiannis D, Chemaly R, Jiang Y, Reitzel R, Raad I. 2009. Utility of galactomannan enzyme immunoassay and (1, 3) β-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. Journal of Clinical Microbiology. 47(1), 129-133. open in new tab
71. Hagiwara D, Takahashi H, Fujimoto M, Sugahara M, Misawa Y, Gonoi T, Itoyama S, Watanabe A, Kamei K. 2016. Multi-azole resistant Aspergillus fumigatus harboring cyp51A TR 46 /Y121F/T289A isolated in Japan. J. Infect. Chemother. 2016. open in new tab
72. Hagiwara D, Watanable A, Kamei K, Goldman G. 2016. Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi. Front. Microbiol. 7, 1382-1389. open in new tab
73. Harmon B. 1998. Avian heterophils in inflammation and disease resistance. Poult. Sci. 77, 972-977. open in new tab
74. Henrici A. 1940. Characteristics of fungous diseases. Journal of Bacteriology. 39, 113-138. open in new tab
75. Hof H. 2001. Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother. 45(11), 2987-2990. open in new tab
76. Hope W, Walsh T, Denning D. 2005. Laboratory diagnosis of invasive aspergillosis. The Lancet Infectious Diseases. 5(10), 609-622. open in new tab
77. Howard S, Arendrup M. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol. 49, 90-95 open in new tab
78. Howard S, Cerar D, Anderson M, Albarrag A, Fisher M, Pasqualotto A, Laverdiere M, Arendrup M, Perlin D, Denning D. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerging Infect. Dis. 15, 1068-1076. open in new tab
79. Howard S, Webster I, Moore C, Gardiner R, Park S, Perlin D, Dening D. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents. 28, 197- 200. open in new tab
80. Hsueh P, Lau Y, Chuang Y, Wan J, Huang W, Shyr J, Yan J, Yu K, Wu J, Ko W, et al. 2005. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: Surveillance of multicenter antimicrobial resistance in Taiwan program data from. Antimicrob. Agents Chemother. 49, 512-517. open in new tab
81. Ingen J, Lee H, Zoll J, Leenstra T, Melchers W, Verweij P. 2015. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. J. Antimicrob Chemother. 70, 178-181.
82. Irinyi L, Lackner M, de Hoog G, Meyer W. 2016. DNA barcoding of fungi causing infections in humans and animals. Fungal Biology. 120(2), 125-136. open in new tab
83. Jacob S, Petraitis V, Small C, Walsh T. 2017. Orphan drugs for the treatment of aspergillosis: focus on isavuconazole. Orphan Drugs: Research and Reviews. 7, 37- 46. open in new tab
84. Jasiński M, Ducos E, Martinoia E, Boutry M. 2003. The ATP-binding cassette transporters: structure, function, and gene family comparison between rice and Arabidopsis. Plant Physiol. 131, 1169-1177. open in new tab
85. Jeurissen A, Cooreman S, Van K, Van L, Vanhove P, Lagrou K, Heytens L. 2012. Invasive pulmonary aspergillosis due to a multi-azole resistant Aspergillus fumigatus. Acta Clin. Belg. 67, 46-48. open in new tab
86. Jingbei R, Xiangxiang J, Qian Z, Yuan Z, Dunli L, Yunlong Y. 2017. Fungicides induced triazole-resistance in Aspergillus fumigatus associated with mutations of TR46/Y121F/T289A and its appearancein agricultural fields. Journal of Hazardous Materials. 324, pp.54-60.
87. Kahle M, Buerge I, Hauser A, Müller M, Poiger T. 2008. Azole fungicides: occurrence and fate in wastewater and surface waters. Environmental Science & Technology. 42(19), pp.7913-7200. open in new tab
88. Kano R, Kohata E, Tateishi A, Murayama S, Hirose D, Shibata Y, Kosuge Y, Inoue H, Kamata H, Hasegawa A. 2015. Does farm fungicide use induce azole resistance in Aspergillus fumigatus? Med. Mycol. 53, 174-177. open in new tab
89. Kathiravan M, Salake A, Chothe A, Dudhe P, Watode R, Mukta M, Gadhwe S. 2012. The biology and chemistry of antifungal agents: a review. Bioorganic and Medicinal Chemistry. 20(19), 5678-5698. open in new tab
90. Kauffman C. 2006. Clinical efficacy of new antifungal agents. Current Opinion in Microbiology. 9(5), 483-488. open in new tab
91. Kayser F, Bienz K, Eckert J, Zinkernagel R. 2007. Mikrobiologia Lekarska. Wydawnictwo Lekarskie PZWL. s. 334-335. open in new tab
92. Kędziora K, Słomiński J, Gil K, Porzezińska M, Gorzewska A. 2008. Invasive aspergillosis of the paranasal sinuses, lung and brain. Pol. Pneumonol. Allergol. 76, 400-406.
93. Kidd S, Goeman E, Meis J, Slavin M, Verweij P. 2015. Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses. 58, 350-355. open in new tab
94. Kikuchi K, Watanabe A, Ito J, Oku Y, Wuren T, Taguchi H, Yarita K, Muraosa Y, Yahiro M, Yaguchi T. 2014. Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan. J. Infect. Chemother. 20, 336-338. open in new tab
95. Klich M. 2006. Identification of clinically relevant aspergilli. Med. Mycol. 59,39- 46. open in new tab
96. Klika E, Scheuermann D, de Groodt-Lasseel M, Bazantova I, Switka A. 1996. Pulmunary macrophages in birds (barn owl, Tyto Tyto alba), domestic fowl (Gallus gallus f. domestica), quail (Coturnix) and pigeons (Columbia livia). Anat. Rec. 246, 87-97. open in new tab
97. Kousha M, Tadi R, Soubani A. 2011. Pulmonary aspergillosis: a clinical review. European Respiratory Review. 20(121), 156-174. open in new tab
98. Kozel T, Wickes B. 2014. Fungal Diagnostics. Cold Spring Harbor Perspectives in Medicine, 4(4), a019299. open in new tab
99. Krishnan K, Feng X, Powers-Fletcher M, Bick G, Richie D, Woollett L, Askew D. 2013. Effects of a defective endoplasmic reticulum-associated degradation pathway on the stress response, virulence, and antifungal drug susceptibility of the mold pathogen Aspergillus fumigatus. Eukaryotic Cell. 12(4), 512-519. open in new tab
100. Krishnan S, Manavathu E, Chandrasekar P. 2009. Aspergillus flavus: An emerging non-fumigatus Aspergillus species of significance. Mycoses 52, 206-222. open in new tab
101. Krzyściak P, Macura A, Skóra M. 2011. Atlas grzybów chorobotwórczych człowieka. MedPharm Polska.
102. Kurzyk E, Nawrot U, Mroczyńska M, Włodarczyk K, Ussowicz, Zdziarski P, Arendrup M, Brillowska-Dąbrowska A. 2015. Detection of clinical Aspergillus fumigatus isolates resistant to triazoles. 7th Trends in Medical Mycology, Lizbona, Mycoses. 53 -54.
103. La Pape P, Lavergne R, Morio F, Alvarez C. 2015. Description of multiple fungicide driven alterations in azole-resistant Aspergillus fumigatus in Colombia, South America. Emerg Infect Dis. 21-22:30-40.
104. Lamb D, Kelly D, Kelly S. 1999. Molecular aspects of azole antifungal action and resistance. Drug Resistance Updates. 2(6), 390-402. open in new tab
105. Lamoth F, Juvvadi P, Soderblom E, Moseley M, Asfaw Y, Steinbach W. 2014. Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy. 58(4), 1889-1896. open in new tab
106. Lane J, Clayton D, Thoday K, Thomsett L. 1974. The diagnosis and successful treatment of Aspergillus fumigates infection of the frontal sinuses and nasal chambers of the dog. Journal of Small Animal Practice. 15(2), 79-87. open in new tab
107. Lavergne R, Morio F, Favennec L, Dominique S, Meis J, Gargala G, Verweij P, Le Pape P. 2015. First description of azole-resistant Aspergillus fumigatus due to TR 46 /Y121F/T289A mutation in France. Antimicrob. Agents Chemother. 2015, 59, 4331-4335. open in new tab
108. Lelivre L, Groh M, Angebault C, Maherault A, Didier E, Bougnoux M. 2013. Azole resistant Aspergillus fumigatus: an emerging problem. Med. Mal. Infect. 43, 139-145. open in new tab
109. Lepage O, Perron M, Cadore J. 2004. The mystery of fungal infection in the guttural pouches. Vet. J. 68, 60-64. open in new tab
110. Lepesheva G, Hargrove T, Kleshchenko Y, Nes W, Villalta F, Waterman M. 2008. CYP51: A major drug target in the cytochrome P450 superfamily. Lipids. 43(12), 1117-1125. open in new tab
111. Lescar J, Meyer I, Akshita K, Srinivasaraghavan K, Verma C, Palous M, Mazier D, Datry A, Fekkar A. 2014. Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole. J. Antimicrob. Chemother. 69, 3244-3247. open in new tab
112. Latgé, J. 1999. Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews. 12(2), 310-350.
113. Li J, Nguyen C, Garcia-Diaz J. 2015. Role of new antifungal agents in the treatment of invasive fungal infections in transplant recipients: isavuconazole and new posaconazole formulations. Journal of Fungi. 1(3), pp.345-366. open in new tab
114. Liu W, Sun Y, Chen W, Liu W, Wan Z, Bu D, Li R. 2012. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob. Agents Chemother. 56, 2598-2603. open in new tab
115. Lockhar S. 2015. Azole resistance in the Americas: Not catching up with europe (yet). In Proceedings of the 7 th Trends in Medical Mycology, Lisbon, Portugal, 9-12 October 2015; Volume 58, p. 20.
116. Lockhart S, Frade J, Etienne K, Pfaller M, Diekema D, Balajee S. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrobial Agents and Chemotherapy. 55(9), pp.4465-4468. open in new tab
117. Malinowska E, Jankowski K, Wyrębek H, Truba M. 2015. Struktura sprzedaży i zużycia środków ochrony roślin w Polsce w latach 2000-2012. Zeszyty Naukowe Uniwersytetu Przyrodniczo-Humanistycznego w Siedlcach Seria Administracja i Zarządzanie. 104, pp.173-185. open in new tab
118. Manavathu E, Espinel-Ingroff A, Alangaden G, Chandrasekar P. 2003. Molecular studies on voriconazole resistance in a clinical isolates of Aspergillus fumigatus. In proceedings of 43 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 14-17 September, 2003.
119. Mani A, Rahwan I, Pentland A. 2013. Inducing peer pressure to promote cooperation. Scientific Reports. 3(1735), pp.1-9. open in new tab
120. Mayr A., Lass-Flörl C. 2011. Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature. Eur. J. Med. Res. 16, 153-157. open in new tab
121. Mazerski J. 2009. Statystyczna analiza wyników doświadczalnych. Wydawnictwo Malmut.
122. Meis J, Chowdhary A, Rhodes J, Fisher M, Verweij P. 2016. Clinical implication of globally emerging azole resistance in Aspergillus fumigates. Biological Sciences. Phil. Trans. R. Soc. B. 371, 1-10. open in new tab
123. Mellado E, Diaz-Guerra T, Cuenca-Estrella M, Rordiguez-Tudela J. 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin. Microbiol. 39(7), 2431-2438. open in new tab
124. Mellado E, Garcia-Effron G, Alcazar-Fouli L, Cuenca-Estrella M, Rodriguez- Tudela J. 2004. Substitutions at metionine 220 in the 14l-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agenst Chemother. 48(7), 2747-2750. open in new tab
125. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers W, Verweij P, Cuenca- Estrella M, Rodriguez-Tudela J. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrobial Agents and Chemotherapy. 51(6), 1897-1904. open in new tab
126. Micheli P. 1976. Nova planetarium genera: iuxta Tournefortii methodum disposita. Florence: Bernardi Paperinii. 1729.
127. Mohammadi F, Hashemi S, Zoll J, Melchers W, Rafati H, Dehghan P, Rezaie S, Tolooe A, Tamadon Y. van der Lee H. et al. 2015. Quantitative analysis of single- nucleotide polymorphism for rapid detection of TR 34 . Antimicrob. Agents Chemother. 60, 387-392. open in new tab
128. Montesinos I, Dodemont M, Lagrou K, Jacobs F, Etienne I, Denis O. 2014. New case of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in Belgium. J. Antimicrob. Chemother. 69, 3439-3440. open in new tab
129. Mortensen K, Jensen R, Johansen H, Skov M, Pressler T, Howard S, Leatherbarrow H, Mellado E, Arendrup M. 2011. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: A laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 49, 2243-2251. open in new tab
130. Mortensen K, Mellado E, Lass-Florl C, Rodriguez-Tudela J, Johansen H, Arendrup M. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other Aspergillus in Austria, Denmark and Spain. Antimicrob Agents Chemother. 54(11), 4545-4549. open in new tab
131. Mosquera J, Denning D. 2002. Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 46, 556-557. open in new tab
132. Moye-Rowley W. 2015. Multiple mechanisms contribute to the development of clinical significant azole resistance in Aspergillus fumigatus. Frontier in Microbiology. 6, 70, 1-6. open in new tab
133. Nascimento A, Goldman G, Park S, Marras S, Delmas G, Oza U, Lolans K, Dudley M, Mann P, Perlin D. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 47(5), 1719-1726. open in new tab
134. Nawrot U, Kurzyk E, Arendrup M, Mroczyńska M, Włodarczyk K, Sulik- Tyszka B, Wróblewska M, Ussowicz M, Zdziarski P, Niewińska K, Brillowska- Dąbrowska A. 2018. Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles. Med. Mycol. 56(1), 212-124. open in new tab
135. Ngo H, Garneau-Tsodikova S, Green K. 2016. A complex game of hide and seek: the search for new antifungals. Med Chem Comm. 7(7), pp.1285-1306. open in new tab
136. Nowicka U, Wiatr E, Jakubowska L, Polubiec-Kownacka M. 2011. Alergiczna aspergiloza oskrzelowo-płucna imitująca guz płuca u chorej bez astmy oskrzelowej -opis przypadku." Via Medica, Pneumonol. Alergol. Pol. 80(1), 77-81
137. Odds F, Brown A, Gow N. 2003. Antifungal agents: mechanisms of action. Trends in Microbiology. 11(6), 272-279. open in new tab
138. Ozhak-Baysan B, Alastruey-Izquierdo A, Saba R, Ogunc D, Ongut G, Timuragaoglu A, Arslan G, Cuenca-Estrella M, Rodriguez-Tudela J. 2010. Aspergillus alliaceus and Aspergillus flavus co-infection in an acute myeloid leukemia patient. Med. Mycol. 48, 995-999. open in new tab
139. Ozmerdiven G, Ak S, Ener B. 2015. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR 34 L98H mutations in Thurkey. J. Infect. Chemother. 21, 581-586. open in new tab
140. O'Neill J. 2015. Antimicrobials in agriculture and the environment. Reducing unnecessary use and waste. The review on antimicrobial resistance tackling drug- resistant infections globally. 2015.
141. Panackal A, Parisini E, Proschan M. 2014. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. International Journal of Infectious Diseases. 28, pp.80-94. open in new tab
142. Patterson K, Strek M. 2010. Allergic bronchopulmonary aspergillosis. Proceedings of the American Thoracic Society. 7(3), 237-244. open in new tab
143. Paul R, Rudramurthy S, Meis, J, Mouton J, Chakrabarti A. 2015. A novel Y319H substitution in cyp51C associated with azole resistance in Aspergillus flavus. Antimicrob Agents Chemother. 59, 6615-6619. open in new tab
144. Paul S, Diekema D, Moye-Rowley W. 2016. Contributions of both ATP-binding cassette transporter and CYP51A proteins are essential for azole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy. 61(5), 02748- 02762. open in new tab
145. Paulsen I, Brown M, Skurray R. 1996. Proton-dependent multidrug efflux systems. Microbiological Reviews. 60(4), 575-608. open in new tab
146. Pelaez T, Gijon P, Bunsow E, Bouza E, Sanchez-Yerba W, Valerio M, Gama B, Cuenca-Estrella M, Mellado E. 2012. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. J. Clin. Microbiol. 50, 2531-2534. open in new tab
147. Pelaez T, Monteiro M, Garcia-Rubio R, Bouza E, Gomez-Lopez A, Mellado E. 2015. First detection of Aspergillus fumigatus azole-resistant strain due to cyp51A TR 46 /Y121F/T289A in an azole-naive patient in Spain. New Microbes. New Infect. 6, 33-34. open in new tab
148. Perlin D, Shor E, Zhao Y. 2015. Update on Antifungal Drug Resistance. Current Clinical Microbiology Reports. 2(2), 84-95.Perveen I, Sehar S, Naz I, Ahmed S. 2016. Prospective evaluation of azole resistance in Aspergillus fumigatus clinical isolates in Pakistan. In Proceedings of 7th Advances Against Aspergillosis, Manchester, UK, 3-5 March 2016. open in new tab
149. Pfaffl M. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29(9), 203-207. open in new tab
150. Pfaller M, Messer S, Rhomberg P, Jones R, Castabheira M. 2013. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. Journal of Clinical Microbiology. 51(8), 2608-2616. open in new tab
151. Podust L, Poulos T, Waterman M. 2001. Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A. 98(6), 3068-3073. open in new tab
152. Prigitano A, Venier V, Cogliati M, De Lorenzis G, Esposto M, Tortorano A. 2014. Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012. Euro Surveill. 19, 20747. open in new tab
153. Qiao J, Liu W, Li R. 2010. Truncated Afyap1 attenuates antifungal susceptibility of Aspergillus fumigatus to voriconazole and confers adaptation of the fungus to oxidative stress. Mycopathologia. 170(3), 155-160. open in new tab
154. Rajendran R, Mowat E, McCuttoch E, Lappin D, Jones B, Lang S, Majithiya J, Warn P, Williams C, Ramage G. 2011. Azole resistance of Aspergillus fumigatus biofilms is partly assiociated with efflux pump activity. Antimicrob. Agents Chemother. 2092-2097. open in new tab
155. Rath P, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. 2012. First reported case of azole-resistant Aspergillus fumigatus due to the TR 34 /L98H mutation in Germany. Antimicrob. Agents Chemother. 56, 6060-6061. open in new tab
156. Rocchi S, Daguindau E, Grenouillet F, Deconinck E, Bellanger A, Garcia- Hermoso D, Bretagne S, Reboux G, Millon L. 2014. Azole-resistant Aspergillus fumigatus isolate with the TR 34 /L98H mutation in both a fungicide sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis. J. Clin. Microbiol. 52, 1724-1726. open in new tab
157. Rodriguez-Tudela J, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52, 2468- 2472. open in new tab
158. Rodriquez-Tudela J, Donnelly J, Arendrup M, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning D, Fegeler W, Gaustad P, Lass-Flörl C, Moore C, Richardson M, Schmalreck A, Velegraki A, Verweij P. 2008. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 14, 982-984. open in new tab
159. Ramakrishnan J, Rathore S, Raman T. 2016. Review on fungal enzyme inhibitors -potential drug targets to manage human fungal infection. The Royal Society of Chemistry Advances. 6(48), pp.42387-42401. open in new tab
160. Rath P, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. 2012. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob. Agents Chemother. 56, 6060-6061. open in new tab
161. Ren J, Jin X, Zhang Q, Zheng Y, Lin Y, Yu Y. 2017. Fungicides inducted triazole-resistance in Aspergillus fumigatus associated with mutations of TR 46 /Y121F/T289A and its appearance in agricultural fields. J. Hazard. Mater. 326, 54-60. open in new tab
162. Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M. 2016. Triazole resistance in Aspergillus spp.: a worldwide problem? Journal of Fungi. 2(3). open in new tab
163. Rocchi S, Daguindau E, Grenouillet F, Deconinck E, Bellanger A, Garcia- Hermoso D, Bretagne S, Reboux G. Millon L. 2014. Azole-resistant Aspergillus fumigatus isolate with the TR34/ L98H mutation in both a fungicide-sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis. Journal of Clinical Microbiology. 52(5), pp.1724-1726. open in new tab
164. Sanglard D. 2016. Emerging threats in antifungal-resistatn fungal pathogens. Front. Med. 3:11, 1-10 open in new tab
165. Sarfati J, Jensen H, Letage J. 1996. Route of infections in bovine aspergillosis. J. Med. Vet. Mycol. 34, 379-383. open in new tab
166. Seyedmousavi S, Brüggemann R, Melchers W, Rijs A, Verweij P, Mouton J. 2013. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. Journal of Antimicrobial Chemotherapy. 68, pp.385-393. open in new tab
167. Shapiro R, Robbins N, Cowen L. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiology and Molecular Biology Reviews, 75(2), 213-267. open in new tab
168. Sharma C, Hagen F, Moroti R, Meis J, Chowdhary A. 2015. Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired? J. Glob. Antimicrob. Resist. 2015. open in new tab
169. Shyadehi A, Lamb D, Kelly S, Kelly D, Schunck W, Wright J. 1996. The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: lanosterol 14 alphademethylase P-45014DM, and CYP51). J Biol Chem. 271, 12445-12450. open in new tab
170. Slaven J, Anderson M, Singlard D, Dixon G, Bille J, Roberts I, Dening D. 2002. Increased expression of a novel Aspergillus fumigatus ABC transporter gene atrF in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal. Genet. Biol. 36, 199-206. open in new tab
171. Snelders E, Rijs A, Kema G, Melchers W, Verweij P. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Applied and Environmental Microbiology. 75(12), 4053-4057. open in new tab
172. Snelders E, Karawajczyk A, Verhoeven R, Venselaar H, Schaftenaar G, Verweij P, Melchers W. 2011. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance. Fungal Genetics and Biology. 48(11), 1062- 1070. open in new tab
173. Snelders E, Camps S, Karawajczyk A, Schaftenaar G, Kema G, Van der Lee H, Klaassen C, Melchers W, Verweij P. 2012. Triazole fungicides can induce cross- resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 7(3) 1-15. open in new tab
174. Snelders E, van der Lee H, Kuijpers J, Rijs A, Varga J, Samson R, Mellado E, Donders A, Melchers W, Verweij P. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5, e219. open in new tab
175. Steinmann J, Hamprecht A, Vehreschild M, Cornely O, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis J, Rath P. 2015. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J. Antimicrob. Chemother. 70, 1522-1526. open in new tab
176. Sulik-Tyszka B, Cieślik J, Snarski E, Waszczuk-Gajda A, Wróblewska M. 2016. Aktywność in vitro izawukonazolu wobec klinicznych szczepów z rodzaju Candida i Aspergillus. Forum Zakażeń. 7(3), pp.135-139. open in new tab
177. Soubani A, Chandrasekar P. 2002. The clinical spectrum of pulmonary aspergillosis. CHEST Journal, 121(6), 1988-1999. open in new tab
178. Stanestu A, Ochiuz L, Cojocaru I, Popovici I, Lupuleasa D. 2010. The influence of different polymers on the pharmaco-technological characteristics of propiconazole nitrate bioadhesive oromucosal tablets. Farmacia. 58(3), 279-283. 168. Stens old C, Jørgensen L, Arendrup M. 2012. Azole-resistant invasive aspergillosis: relationship to agriculture. Current Fungal Infection Reports. 6(3), 178-191.
179. Sugui J, Kwon-Chung H, Juvvadi P, Letage P, Steinbach W. 2015. Aspergillus fumigatus and related species. Cold. Spring. Harb. Perspect. Med. 5, 1-17. open in new tab
180. Taccone F, Able V, Bulpa A, Misset P, Meersseman W, Cordaso T. 2015. Epidemiology of invasive aspergillosis in critical ill patients: clinical presentation, underlying conditions, and outcomes. Crit. Care. 19, 7. open in new tab
181. Tell L. 2005. Aspergillosis in mammals and birds: impact on veterinary medicine. Medical Mycology. 43, 71-73. open in new tab
182. Tobin M, Peery R, Skatril L. 1997. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene, 200, 11-23. open in new tab
183. ToyotomeT, Fujiwara T, Kida H, Matsumoto M, Wada T, Komatsu R. 2016. Susceptibility to azoles in clinical isolates of Aspergillus fumigatus and A. tubingensis from Obihiro, Japan. In Proceedings of 7th Advances Against Aspergillosis, Manchester, UK, 3-5 March 2016. open in new tab
184. Trösken E, Bittner N, Völkel W. 2005. Quantitation of 13 azole fungicides in wine samples by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. 1083(1-2), pp.113-119. open in new tab
185. Tyburski J, Studzińska A, Daca P, Tretyn A. 2008. PCR w czasie rzeczywistym. Metody analiz danych. Biotechnologia. 1(80), 86-96.
186. Wahl E, Erickson M. 1928. Primary pulmonary Aspergillosis. Journal of the Medical Association of Georgia. 17, 341-348.
187. Wang D, Gricourt M, Arne P, Thierry S, Seguin D, Chermette R, Huang W, Dannaoui E, Botterel F, Guillot J. 2014. Mutations in the Cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus isolated from avian farms in France and China. Poult. Sci. 93, 12-15. open in new tab
188. Wei X, Zhang Y, Lu L. 2015. The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back. Journal of Microbiology. 53(2), 91-99. open in new tab
189. White T, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. PCR -Protocols and Applications. pp. 315-322. open in new tab
190. Wiederhold N, Garcia G, Lindner J. 2015. Evaluation of Cyp51A mechanisms of azole resistance in Aspergillus fumigatus isolates from the United States. Mycoses. 58.
191. Wiederhold N, Gil V, Gutierrez F, Lindner J, Albataineh M, McCarthy D, Sanders C, Fan H, Fothergill A, Sutton D. 2016. First detection of TR 34 /L98H and TR 46 /Y121F/T289A cyp51 mutations in Aspergillus fumigatus isolates in the United States. J. Clin. Microbiol. 2016, 54, 168-171. open in new tab
192. Willger S, Puttikamonkul S, Kim K, Burritt J, Grahl N, Metzler L, Barbuch R, Bard M, Lewrence C, Cramer R. 2008. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLOS Pathog. 4, e1000200 open in new tab
193. Wu C, Wang H, Lee J, Lo H, Dai C, Chou P, Ko W, Chen Y. 2015. Azole- resistant Aspergillus fumigatus isolates carrying TR34/L98H mutations in Taiwan. Mycoses. 58. open in new tab
194. Valiante V, Macheleidt J, Föge M, Brakhage A. 2015. The Aspergillus fumigatus cell wall integrity signaling pathway: drug target, compensatory pathways, and virulence. Frontiers in Microbiology.16, 6-32 open in new tab
195. Valsecchi I, Mellado E, Beauo R, Raj S, Letage J. 2015. Fitness studies of azole- resistant strains of Aspergillus fumigatus. Antimicrob. Agents Chemother, 59(12), 7866-7869. 186. van der Linden J, Snelders E, Kampinga G, Rijnders B, Mattsson E, Debets- Ossenkopp Y, Kuijper E, Van Tiel F, Melchers W, Verweij P. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007- 2009. Emerg. Infect. Dis. 17, 1846-1854.
196. Van der Linden J, Arendrup M, Warris A, Lagrou K, Pelloux H, Hauser P, Chryssanthou E, Mellado E, Kidd S, Tortorano A, Dannaoui E, Gaustad P, Baddley J, Uekötter A, Lass-Flörl C, Klimko N, Moore C, Denning D, Pasqualotto A, Kibbler C, Arikan-Akdagli S, Andes D, Meletiadis J, Naumiuk L, Nucci M, Melchers W, Verweij P. 2015. Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus. Emerging Infectious Diseases. 21, 6, 1041-1044. open in new tab
197. Van der Linden J, Camps S, Kampinga G, Arends J, Debets-Ossenkopp Y, Haas P, Rijnders B, Kuijper E, van Tiel F, Varga J. 2013. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin. Infect. Dis. 57, 513-520. 189. van Ingen J, van der Lee H, Rijs T, Zoll J, Leenstra T, Melchers W, Verweij P. open in new tab
198. Azole, polyene and echinocandin MIC distributions for wild-type, TR 34 /L98H and TR 46 /Y121F/T289A Aspergillus fumigatus isolates in The Netherlands. J. Antimicrob. Chemother. 70, 178-181.
199. Vazquez J, Manavathu K. 2016. Molecular Characterization of a Voriconazole- Resistant, Posaconazole-Susceptible Aspergillus fumigatus Isolate in a Lung Transplant Recipient in the United States. AAC. 60: 2. 1129-1134. open in new tab
200. Vermeulen E, Lagrou K, Verweij P. 2013. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr. Opin. Infect. Dis. 26, 493-500. open in new tab
201. Vermeulen E, Maertens J, De Bel A. 2015. Nationwide surveillance of azole resistance in Aspergillus diseases. Antimicrob. Agents Chemother. 59, 4569-4576. open in new tab
202. Vermeulen E, Maertens J, Schoemans H, Lagrou K.2012. Azole-resistant Aspergillus fumigatus due to TR 46 /Y121F/T289A mutation emerging in Belgium, July 2012. Euro. Surveill. 17, pii20326.
203. Verweij P, Dorsthorst D, Rijs A, de Vries-Hospers H, Meis J. 2002. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolated cultured between 1945 and 1998. Journal of Clinical Microbiology. 40(7), 2648-2650. open in new tab
204. Verweij P, Latage P, Rijs A, Pauw P, Hoogkamp-Korstanje J, Meis J. 1995. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J. Clin. Microbiol. 33(12) 3150-3153. open in new tab
205. Verwiej P, Mellado E, Melchers W. 2007. Multiple-triazole-resistant aspergillosis. N.Eng. J. Med. 356.1481-1483. open in new tab
206. Verweij P, Snelders E, Kema G, Mellado E, Melchers W. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? The Lancet Infectious Diseases. 9(12) pp.789-795. open in new tab
207. Verweij P, Chowdhary A, Melchers W, Meis J. 2016. Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? CID. 62, 1-7. open in new tab
208. Xiao L, Madison V, Chau A, Loebenberg D, Palermo R, McNicholas P. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrobial Agents and Chemotherapy. 48(2), 568-574. open in new tab
209. Xiong Q, Hassan S, Wilson W, Han X, May G, Tarrand J, Matsuda S. 2005. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrobial Agents and Chemotherapy. 49(2), 518-524. open in new tab
210. Zhang M, Feng C, Chein F, He Q, Su Q, Shi Y. 2017. Triazole resistance in Aspergillus fumigatus clinical isolates obtained in Nanjing, China. Chinese Medical Journal. 20(6), 665-668. open in new tab
211. Zhang J, Snelders E, Zwaan B, Schoustra S, Meis J, van Dijk K, Hagen F, van der Beek M, Kampinga G, Zoll J, Melchers W, Verweij P, Debets A. 2017. A novel environmetak azole resistant mutation in Aspergillus fumigatus and a possible role of sexual reproduction in its emergence. American Society for Microbiology. 8(3)00791-17. open in new tab
212. Zhao Y, Stensvold C, Perlin D, Arendrup M. 2013. Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases. J. Antimicrob. Chemother. 68, 1497-1504. open in new tab
213. Ziółkowska G, Tokarzewski S, Nowakiewicz A. 2014. Drug resistance of Aspergillus fumigatus strains isolated from flocks of domestic geese in Poland. Poultry Science. 93(5), pp.1106-1112. open in new tab
214. Zonderland J, Strok C, Saunders J. 2002. Intranasal infusion of enilconazole for treatment of sinonasal aspergillosis in dog. J. Am. Vet. Med. Assoc. 221, 1421-1425. open in new tab
215.  Kurzyk E.: "Budowa biofilmu chorobotwórczych drożdży i jego wpływ na oporność." Dokonania Młodych Naukowców nr 5 s. 266-267, 2014
216. Prezentacje ustne na konferencjach:  Kurzyk E., "Oporność izolatów Aspergillus fumigatus na izawukonazol" Ogólnopolska Konferencja Biotechnologów i Mikrobiologów BioMillenium 2017, Gdańsk 6-8 wrzesień 2017.
217.  Kurzyk E.: "Quorum sensing -rola w patogenezie drożdży Candida. Wpływ Młodych Naukowców na osiągnięcia Polskiej Nauk, VI Edycja, Gdańsk 25.04.2014
218. Plakaty na konferencjach:  Nawrot U., Wieliczko A., Kurzyk E., Brillowska-Dąbrowska A.: "Low frequency of itraconazole resistance fund among avian Aspergillus fumigatus isolates" 8 th Trends in Medical Mycology, Mycoses. Serbia, 06-09.10.2017.
219.  Kurzyk E., Mroczyńska M., Nawrot U., Włodarczyk K., Brillowska-Dąbrowska A.: " Oporność izolatów Aspergillus fumigatus na azole" XXVII Zjazd Polskiego Towarzystwa Mikrobiologów. Bydgoszcz 25-27.09.2016
220.  Kurzyk E., Nawrot U., Włodarczyk K., Brillowska-Dąbrowska A.: "Występowanie tandemowych powtórzeń (TR 34 ) w rejonie promotora genu CYP51A oraz mutacji w tym genie jako czynników predysponujących do oporności na azole wśród izolatów Aspergillus fumigatus" II Ogólnopolska Konferencja "Drobnoustroje w świecie człowieka -Drobnoustroje oportunistyczne" Bydgoszcz 21-22.05.2016. -praca wyróżniona I miejscem w sesji plakatowej  Mroczyńska M., Kurzyk E., Brillowska-Dąbrowska A., Gucwa K., Szweda P.: Genotypowanie klinicznych izolatów Candida albicans metodą MP PCR" II Ogólnopolska Konferencja "Drobnoustroje w świecie człowieka -Drobnoustroje oportunistyczne" Bydgoszcz 21-22.05.2016.
221.  Kurzyk E., Mroczyńska M., Nawrot U., Włodarczyk K., Brillowska-Dąbrowska A.: "Czy istnieje konieczność oznaczania oporności na azole dla szczepów Aspergillus fumigatus izolowanych w Polsce?" BioMedSession, Gdańsk 12.12.2015
222.  Kurzyk E., Nawrot U., Mroczyńska M., Włodarczyk K., Ussowicz M., Zdziarski P., Arendrup MC., Brillowska-Dąbrowska A.: Detection of clinical Aspergillus fumigatus isolates resistant to triazoles. 7th Trends in Medical Mycology. Vol. 58 Supplement S4. P006. str. 53-54. Lizbona 9-12 październik 2015
223.  Nawrot U., Kurzyk E., Włodarczyk K., Ussowicz M., Arendrup MC., Brillowska-Dąbrowska A.: The first Polish report of azole resistant clinical Aspergillus fumigatus isolate. 6th International Weigl Conference on Microbiology. Acta Biochemica Polonica. Vol. 62 Supplement 2/2015. V.P.38. str. 104. Gdańsk, 8-10 lipiec 2015
224.  Kurzyk E., Kadzewicz K., Romanowska E., Dzierżanowska-Fangrat K., Brillowska-Dąbrowska A., Szweda P.: "Genotypowanie klinicznych izolatów Candida krusi. " I Ogólnopolska Konferencja "Drobnoustroje oportunistyczne" Bydgoszcz 18-20 wrzesień 2014

show (224) hide

Sources of funding:

• Praca współfinansowana ze środków NCN w ramach projektu OPUS nr 2013/11/B/NZ7/04935:

Verified by:

Gdańsk University of Technology